UNSPSC 51313430: Doxylamine hydrogen succinate

This classification denotes a histamine-1 receptor antagonist with the molecular formula C17H22N2O.C4H6O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier V9BI9B5YI2, chemically known as succinic acid, compd. with 2-(alpha-(2-(dimethylamino)ethoxy)-alpha-methylbenzyl)pyridine (1:1) (8ci) but more generally known as doxylamine hydrogen succinate, which bears US NIH Compound Identifier 11224.

European Medicines Agency schedules Doxylamine hydrogen succinate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11925MIG. Most nations, for tariff and trade purposes, schedule doxylamine hydrogen succinate under HS 29333999. SMILES: CC(C1CCCCC1)(C2CCCCN2)OCCN(C)C.C(CC(=O)O)C(=O)O.

UNSPSC 51313430 Doxylamine hydrogen succinate is a Commodity code that encompasses pharmaceutical ingredients and finished medications, though recent state and local procurement activity under this code does not focus on doxylamine specifically. The three most recent opportunities tagged to this code are actually purchasing naloxone (an opioid antagonist), therapeutic pharmacy initiative services, and generic multi-source pharmaceuticals and OTC products through cooperative arrangements. State and local governments use codes in this family to procure prescription medications, over-the-counter drugs, and pharmaceutical ingredients through direct purchase agreements, pharmacy benefit programs, and cooperative purchasing vehicles that aggregate demand across multiple jurisdictions. Issuing bodies include county health departments, state health and human services commissions, and multi-state cooperative purchasing alliances that serve state agencies, local governments, and healthcare facilities.

Recent activity spans Florida, Texas, and Minnesota. Seminole County, Florida issued IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the County Community Health Building, with a response deadline of July 26, 2023. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026 to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program that would establish direct relationships between the state pharmacy benefit program and manufacturers outside traditional pharmacy benefit manager and group purchasing organization channels. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered through the Minnesota Department of Administration's Office of State Procurement, issued RFP S1070000015802 in January 2026 to establish multiple contracts for generic pharmaceuticals and OTC products distributed across participating state and local facilities in Minnesota and Oregon, with proposals due March 26, 2026 and contract effectiveness targeted for July 1, 2026. MMCAP requires vendors to work through three authorized wholesalers and certify compliance with current Good Manufacturing Practices and the Drug Supply Chain Security Act.